Symbols / IOBT $0.18 +1.71%
IOBT Chart
About
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 12.87M |
| Enterprise Value | 110.80K | Income | -88.35M | Sales | — |
| Book/sh | 0.01 | Cash/sh | 0.43 | Dividend Yield | — |
| Payout | 0.00% | Employees | 80 | IPO | — |
| P/E | — | Forward P/E | -0.48 | PEG | — |
| P/S | — | P/B | 13.76 | P/C | — |
| EV/EBITDA | -0.00 | EV/Sales | — | Quick Ratio | 1.73 |
| Current Ratio | 2.01 | Debt/Eq | 1988.91 | LT Debt/Eq | — |
| EPS (ttm) | -1.34 | EPS next Y | -0.37 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 08:00 | ROA | -88.58% |
| ROE | -240.48% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 71.95M |
| Shs Float | 38.31M | Short Float | 8.47% | Short Ratio | 1.81 |
| Short Interest | — | 52W High | 2.79 | 52W Low | 0.14 |
| Beta | 0.44 | Avg Volume | 10.38M | Volume | 1.39M |
| Target Price | $2.18 | Recom | None | Prev Close | $0.18 |
| Price | $0.18 | Change | 1.71% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$2.18
Mean price target
2. Current target
$0.18
Latest analyst target
3. DCF / Fair value
$-12.27
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.18
Low
$0.36
High
$4.00
Mean
$2.18
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-26 | down | Piper Sandler | Overweight → Neutral | $1 |
| 2025-10-22 | main | Piper Sandler | Overweight → Overweight | $3 |
| 2025-09-30 | down | TD Cowen | Buy → Hold | — |
| 2025-09-29 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-08-12 | main | Morgan Stanley | Overweight → Overweight | $4 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-03-05 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-06 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-09-16 | main | Morgan Stanley | Overweight → Overweight | $6 |
| 2024-09-16 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-09-03 | main | Piper Sandler | Overweight → Overweight | $10 |
| 2024-09-03 | main | Morgan Stanley | Overweight → Overweight | $4 |
| 2024-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-05-15 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-03-06 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2023-09-28 | init | Piper Sandler | — → Overweight | $10 |
| 2023-09-13 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2023-08-15 | main | Morgan Stanley | Overweight → Overweight | $7 |
- IOBT Stock Price and Chart — NASDAQ:IOBT - TradingView ue, 10 Mar 2026 01
- IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why - Yahoo Finance Wed, 19 Nov 2025 08
- Cancer vaccine maker IO Biotech cuts staff, hires Raymond James - Stock Titan Fri, 30 Jan 2026 08
- IO Biotech stock plummets after company explores strategic alternatives - Investing.com Wed, 21 Jan 2026 08
- IOBT IO Biotech, Inc. (NASDAQ) $0.47 on 22 Jan 2026: active intraday mover for traders - Meyka hu, 22 Jan 2026 08
- New Analyst Forecast: $IOBT Given $3.0 Price Target | IOBT Stock News - Quiver Quantitative Wed, 22 Oct 2025 07
- Piper Sandler Downgrades IO Biotech (IOBT) to Neutral, Lowers Pr - GuruFocus Mon, 26 Jan 2026 08
- Cancer vaccine developer weighs sale, merger or liquidation - Stock Titan Wed, 21 Jan 2026 08
- IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance Wed, 03 Sep 2025 07
- $IOBT stock is up 8% today. Here's what we see in our data. - Quiver Quantitative ue, 02 Sep 2025 07
- IO Biotech stock tumbles after Piper Sandler downgrades on strategic review - Investing.com Mon, 26 Jan 2026 08
- IO Biotech (NASDAQ: IOBT) $30.7M cash, runway to Q1 2026, Phase 3 melanoma - Stock Titan Fri, 14 Nov 2025 08
- Private equity firms are IO Biotech, Inc.'s (NASDAQ:IOBT) biggest owners and were rewarded after market cap rose by US$16m last week - Yahoo Finance Wed, 16 Jul 2025 07
- IO Biotech stock plummets after FDA recommends against BLA submission - Investing.com Mon, 29 Sep 2025 07
- IO Biotech (IOBT) launches restructuring, CMO exit and up to $2.6M charges - Stock Titan Fri, 30 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 15000 | 20884 | — | Purchase at price 1.39 per share. | HUNTER HEIDI | Director | — | 2025-05-30 00:00:00 | D |
| 1 | 12000 | 9720 | — | Purchase at price 0.81 per share. | SMITH DEVIN WHITTEMORE | General Counsel | — | 2024-12-23 00:00:00 | D |
| 2 | 12500 | 10120 | — | Purchase at price 0.81 per share. | ZOCCA MAI-BRITT | Chief Executive Officer | — | 2024-12-23 00:00:00 | D |
| 3 | 10250 | 8483 | — | Purchase at price 0.83 per share. | SULLIVAN AMY B. | Chief Financial Officer | — | 2024-12-23 00:00:00 | D |
| 4 | 31350 | 26553 | — | Purchase at price 0.85 per share. | AHMAD QASIM IFTIKHAR | Officer | — | 2024-12-23 00:00:00 | D |
| 5 | 75000 | 99125 | — | Sale at price 1.31 - 1.33 per share. | NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | — | 2024-07-26 00:00:00 | D |
| 6 | 658809 | 802495 | — | Sale at price 1.22 per share. | NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | — | 2024-05-10 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -789.58K | 72.82K | 2.34K | 70.18K |
| TaxRateForCalcs | 0.22 | 0.22 | 0.02 | 0.22 |
| NormalizedEBITDA | -90.74M | -91.02M | -69.47M | -67.77M |
| TotalUnusualItems | -3.59M | 331.00K | 130.00K | 319.00K |
| TotalUnusualItemsExcludingGoodwill | -3.59M | 331.00K | 130.00K | 319.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -95.49M | -86.08M | -71.46M | -67.88M |
| ReconciledDepreciation | 849.00K | 756.00K | 540.00K | 2.00K |
| EBITDA | -94.33M | -90.69M | -69.34M | -67.45M |
| EBIT | -95.18M | -91.44M | -69.88M | -67.45M |
| NetInterestIncome | 4.72M | 5.88M | 1.11M | -361.00K |
| InterestExpense | 0.00 | 302.00K | 361.00K | |
| InterestIncome | 4.72M | 5.88M | 1.41M | 0.00 |
| NormalizedIncome | -92.69M | -86.34M | -71.59M | -68.13M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -95.49M | -86.08M | -71.46M | -67.88M |
| TotalExpenses | 95.18M | 91.44M | 71.42M | 41.23M |
| TotalOperatingIncomeAsReported | -95.18M | -91.44M | -71.42M | -41.23M |
| DilutedAverageShares | 65.88M | 43.54M | 28.82M | 4.34M |
| BasicAverageShares | 65.88M | 43.54M | 28.82M | 4.34M |
| DilutedEPS | -1.45 | -1.98 | -2.48 | -17.30 |
| BasicEPS | -1.45 | -1.98 | -2.48 | -17.30 |
| DilutedNIAvailtoComStockholders | -95.49M | -86.08M | -71.46M | -74.99M |
| NetIncomeCommonStockholders | -95.49M | -86.08M | -71.46M | -74.99M |
| PreferredStockDividends | 7.11M | |||
| NetIncome | -95.49M | -86.08M | -71.46M | -67.88M |
| NetIncomeIncludingNoncontrollingInterests | -95.49M | -86.08M | -71.46M | -67.88M |
| NetIncomeContinuousOperations | -95.49M | -86.08M | -71.46M | -67.88M |
| TaxProvision | 1.44M | 852.00K | 1.27M | 68.00K |
| PretaxIncome | -94.05M | -85.23M | -70.19M | -67.81M |
| OtherIncomeExpense | -3.59M | 331.00K | 130.00K | -26.22M |
| OtherNonOperatingIncomeExpenses | -26.54M | |||
| GainOnSaleOfSecurity | -3.59M | 331.00K | 130.00K | 319.00K |
| NetNonOperatingInterestIncomeExpense | 4.72M | 5.88M | 1.11M | -361.00K |
| InterestExpenseNonOperating | 0.00 | 302.00K | 361.00K | |
| InterestIncomeNonOperating | 4.72M | 5.88M | 1.41M | 0.00 |
| OperatingIncome | -95.18M | -91.44M | -71.42M | -41.23M |
| OperatingExpense | 95.18M | 91.44M | 71.42M | 41.23M |
| ResearchAndDevelopment | 71.48M | 67.83M | 46.99M | 30.15M |
| SellingGeneralAndAdministration | 23.69M | 23.61M | 24.44M | 11.08M |
| GeneralAndAdministrativeExpense | 23.69M | 23.61M | 24.44M | 11.08M |
| OtherGandA | 12.33M | 13.32M | 17.18M | 8.13M |
| SalariesAndWages | 11.37M | 10.29M | 7.26M | 2.96M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 65.88M | 65.88M | 28.82M | 28.82M |
| ShareIssued | 65.88M | 65.88M | 28.82M | 28.82M |
| TotalDebt | 1.92M | 2.49M | 2.79M | 0.00 |
| TangibleBookValue | 47.02M | 133.16M | 138.85M | 211.92M |
| InvestedCapital | 47.02M | 133.16M | 138.85M | 211.92M |
| WorkingCapital | 45.47M | 131.54M | 137.54M | 211.43M |
| NetTangibleAssets | 47.02M | 133.16M | 138.85M | 211.92M |
| CapitalLeaseObligations | 1.92M | 2.49M | 2.79M | 0.00 |
| CommonStockEquity | 47.02M | 133.16M | 138.85M | 211.92M |
| TotalCapitalization | 47.02M | 133.16M | 138.85M | 211.92M |
| TotalEquityGrossMinorityInterest | 47.02M | 133.16M | 138.85M | 211.92M |
| StockholdersEquity | 47.02M | 133.16M | 138.85M | 211.92M |
| GainsLossesNotAffectingRetainedEarnings | -6.85M | -9.67M | -10.14M | -1.49M |
| OtherEquityAdjustments | -6.85M | -9.67M | -10.14M | -1.49M |
| RetainedEarnings | -359.31M | -263.82M | -177.74M | -106.28M |
| AdditionalPaidInCapital | 413.11M | 406.59M | 326.70M | 319.67M |
| CapitalStock | 66.00K | 66.00K | 29.00K | 29.00K |
| CommonStock | 66.00K | 66.00K | 29.00K | 29.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 20.68M | 17.56M | 12.95M | 10.36M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.20M | 1.84M | 2.27M | 59.00K |
| OtherNonCurrentLiabilities | 59.00K | |||
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 1.20M | 1.84M | 2.27M | 0.00 |
| LongTermCapitalLeaseObligation | 1.20M | 1.84M | 2.27M | 0.00 |
| CurrentLiabilities | 19.49M | 15.72M | 10.68M | 10.30M |
| OtherCurrentLiabilities | 500.00K | 563.00K | 1.95M | 461.00K |
| CurrentDebtAndCapitalLeaseObligation | 717.00K | 655.00K | 515.00K | |
| CurrentCapitalLeaseObligation | 717.00K | 655.00K | 515.00K | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.31M | 4.22M | 1.86M | 1.03M |
| PayablesAndAccruedExpenses | 13.96M | 10.27M | 6.35M | 8.82M |
| CurrentAccruedExpenses | 9.30M | 6.40M | 2.34M | 4.89M |
| Payables | 4.66M | 3.88M | 4.00M | 3.93M |
| AccountsPayable | 4.66M | 3.88M | 4.00M | 3.93M |
| TotalAssets | 67.70M | 150.72M | 151.81M | 222.29M |
| TotalNonCurrentAssets | 2.75M | 3.46M | 3.59M | 550.00K |
| OtherNonCurrentAssets | 385.00K | 357.00K | 352.00K | 395.00K |
| NetPPE | 2.36M | 3.11M | 3.23M | 155.00K |
| AccumulatedDepreciation | -577.00K | -330.00K | -115.00K | -12.00K |
| GrossPPE | 2.94M | 3.44M | 3.35M | 167.00K |
| OtherProperties | 2.56M | 3.10M | 3.04M | 68.00K |
| MachineryFurnitureEquipment | 376.00K | 341.00K | 312.00K | 99.00K |
| CurrentAssets | 64.95M | 147.25M | 148.22M | 221.74M |
| OtherCurrentAssets | 1.92M | 2.11M | 2.28M | 3.35M |
| PrepaidAssets | 1.86M | 829.00K | 1.82M | 4.77M |
| Receivables | 1.13M | 1.13M | 1.53M | 2.09M |
| TaxesReceivable | 1.13M | 1.13M | 1.53M | 2.09M |
| CashCashEquivalentsAndShortTermInvestments | 60.03M | 143.19M | 142.59M | 211.53M |
| CashAndCashEquivalents | 60.03M | 143.19M | 142.59M | 211.53M |
| CashEquivalents | 46.13M | 131.61M | 87.97M | |
| CashFinancial | 13.90M | 11.58M | 54.62M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -82.39M | -72.06M | -60.42M | -40.80M |
| IssuanceOfCapitalStock | 0.00 | 75.06M | 0.00 | 265.06M |
| CapitalExpenditure | -44.00K | -323.00K | -690.00K | -153.00K |
| EndCashPosition | 60.30M | 143.46M | 142.86M | 211.80M |
| BeginningCashPosition | 143.46M | 142.86M | 211.80M | 3.40M |
| EffectOfExchangeRateChanges | -771.00K | 803.00K | -8.52M | -3.76M |
| ChangesInCash | -82.39M | -200.00K | -60.42M | 212.15M |
| FinancingCashFlow | 0.00 | 71.86M | 0.00 | 252.95M |
| CashFlowFromContinuingFinancingActivities | 0.00 | 71.86M | 0.00 | 252.95M |
| NetOtherFinancingCharges | -3.20M | -12.11M | ||
| NetPreferredStockIssuance | 0.00 | 149.94M | ||
| PreferredStockIssuance | 0.00 | 149.94M | ||
| NetCommonStockIssuance | 0.00 | 75.06M | 0.00 | 115.11M |
| CommonStockIssuance | 0.00 | 75.06M | 0.00 | 115.11M |
| InvestingCashFlow | -44.00K | -323.00K | -690.00K | -153.00K |
| CashFlowFromContinuingInvestingActivities | -44.00K | -323.00K | -690.00K | -153.00K |
| NetPPEPurchaseAndSale | -44.00K | -323.00K | -690.00K | -153.00K |
| PurchaseOfPPE | -44.00K | -323.00K | -690.00K | -153.00K |
| OperatingCashFlow | -82.35M | -71.74M | -59.73M | -40.65M |
| CashFlowFromContinuingOperatingActivities | -82.35M | -71.74M | -59.73M | -40.65M |
| ChangeInWorkingCapital | 2.18M | 5.86M | 4.19M | -776.00K |
| ChangeInOtherCurrentLiabilities | -639.00K | -604.00K | -139.00K | 0.00 |
| ChangeInOtherCurrentAssets | -29.00K | -4.00K | -44.00K | -25.00K |
| ChangeInPayablesAndAccruedExpense | 3.71M | 4.90M | -203.00K | 7.34M |
| ChangeInAccruedExpense | 2.92M | 5.03M | -280.00K | 3.93M |
| ChangeInPayable | 782.00K | -126.00K | 77.00K | 3.41M |
| ChangeInAccountPayable | 782.00K | -126.00K | 77.00K | 3.41M |
| ChangeInPrepaidAssets | -858.00K | 1.57M | 4.58M | -8.09M |
| OtherNonCashItems | 26.54M | |||
| StockBasedCompensation | 6.53M | 8.06M | 7.04M | 1.79M |
| DeferredTax | 0.00 | 87.00K | 0.00 | |
| DeferredIncomeTax | 0.00 | 87.00K | 0.00 | |
| DepreciationAmortizationDepletion | 849.00K | 756.00K | 540.00K | 2.00K |
| DepreciationAndAmortization | 849.00K | 756.00K | 540.00K | 2.00K |
| Depreciation | 849.00K | 756.00K | 540.00K | 2.00K |
| OperatingGainsLosses | 3.59M | -331.00K | -130.00K | -319.00K |
| NetForeignCurrencyExchangeGainLoss | 3.59M | -331.00K | -130.00K | -319.00K |
| NetIncomeFromContinuingOperations | -95.49M | -86.08M | -71.46M | -67.88M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IOBT
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|